Trevena (NASDAQ: TRVN) 40% HIGHER; announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE